全文获取类型
收费全文 | 4665篇 |
免费 | 260篇 |
国内免费 | 54篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 130篇 |
妇产科学 | 110篇 |
基础医学 | 413篇 |
口腔科学 | 180篇 |
临床医学 | 359篇 |
内科学 | 1490篇 |
皮肤病学 | 84篇 |
神经病学 | 308篇 |
特种医学 | 149篇 |
外科学 | 800篇 |
综合类 | 13篇 |
预防医学 | 174篇 |
眼科学 | 108篇 |
药学 | 232篇 |
中国医学 | 10篇 |
肿瘤学 | 396篇 |
出版年
2024年 | 10篇 |
2023年 | 54篇 |
2022年 | 118篇 |
2021年 | 219篇 |
2020年 | 117篇 |
2019年 | 149篇 |
2018年 | 188篇 |
2017年 | 130篇 |
2016年 | 142篇 |
2015年 | 189篇 |
2014年 | 230篇 |
2013年 | 252篇 |
2012年 | 361篇 |
2011年 | 370篇 |
2010年 | 208篇 |
2009年 | 198篇 |
2008年 | 320篇 |
2007年 | 325篇 |
2006年 | 271篇 |
2005年 | 257篇 |
2004年 | 225篇 |
2003年 | 179篇 |
2002年 | 150篇 |
2001年 | 29篇 |
2000年 | 17篇 |
1999年 | 25篇 |
1998年 | 31篇 |
1997年 | 28篇 |
1996年 | 20篇 |
1995年 | 16篇 |
1994年 | 13篇 |
1993年 | 9篇 |
1992年 | 10篇 |
1991年 | 13篇 |
1990年 | 8篇 |
1989年 | 13篇 |
1988年 | 11篇 |
1987年 | 8篇 |
1986年 | 7篇 |
1985年 | 6篇 |
1983年 | 5篇 |
1980年 | 4篇 |
1976年 | 3篇 |
1975年 | 5篇 |
1974年 | 3篇 |
1973年 | 3篇 |
1970年 | 6篇 |
1969年 | 2篇 |
1967年 | 3篇 |
1966年 | 3篇 |
排序方式: 共有4979条查询结果,搜索用时 0 毫秒
1.
Maria Stella Aniello Davide Martino Gianluca Masi Paolo Livrea Giovanni Defazio 《Movement disorders》2006,21(4):571-575
We developed a self-administered questionnaire for screening the most common adult-onset dystonias. It was tested in 90 first-degree relatives of 22 adult-onset dystonia patients, yielding 79% sensitivity and 94% specificity. Simulation of a case-finding procedure based on serial application of the questionnaire and clinical examination of both subjects screening positive and subjects screening negative who had < 8 years of schooling increased sensitivity to 95% and specificity to 100%. This questionnaire may be an important screening resource for familial aggregation studies to be used in the context of a complex case-finding procedure. 相似文献
2.
3.
The efficiency of a new prothrombin-based activated protein C (APC) resistance test to detect factor V Leiden (FVL) was clinically evaluated in 150 Italian patients with deep venous thrombosis. Patient samples are diluted in factor-V-deficient plasma, an APC-containing reagent, and specific factor V activator; after incubation, clotting is initiated by addition of activated-factor-FV-dependent prothrombin activator. Two prothrombin time determinations were performed under identical assay conditions except that no APC was added to one. A ratio over 4.2 for normal individuals and under 2.0 for FVL patients is expected: between 1.3 and 1.9 for FVL heterozygotes, and between 1.0 and 1.1 for FVL homozygotes. Using a predefined cut-off ratio of 2.0, a specificity and a sensitivity of 1.00 for detection of FVL mutation were found. With a cut-off ratio of 1.1, a specificity of 0.98 and a sensitivity of 1.00 were found for discrimination between FVL heterozygous (n = 60) and homozygous (n = 6). No interferences by heparins, oral contraceptives, oral anticoagulant therapy, protein C, protein S, D-dimer, homocysteine, MTHFR mutations and antiphospholipid autoantibodies were detected. In our experience, this new prothrombin time-based APC resistance assay provides improved discrimination between normal individuals and FVL carriers compared with the classical methods. Moreover, this new assay allows good discrimination between homozygous and heterozygous FVL carriers. In the authors' experience this prothrombin time-based method was not influenced by many factors compared with the classical activated partial thromboplastin time-based method. 相似文献
4.
Gianluca Tamagno 《Indian journal of gastroenterology》2007,26(1):50-1; author reply 51
5.
Rigatelli Gianluca; Cardaioli Paolo; Giordan Massimo; Roncon Loris 《European heart journal》2007,28(1):51
A 65-year-old hypertensive man with shortness of breath andatypical thoracic pain underwent coronary angiography for 相似文献
6.
B P Leheup M Cisternino M Bozzola B Dousset P L Marradi F Antoniazzi L Tato F Severi D Sommelet M Pierson 《Journal of endocrinological investigation》1991,14(1):37-40
Thirty-five patients with thalassemia major, aged 7 to 21 years, were studied to define the relationship between the pubertal development and the growth-hormone (GH) secretion during sleep, after administration of GH-releasing factor (hpGRF 1-44), and betaxolol-glucagon or arginin-insulin. Pubertal development was classified as being appropriate or delayed for chronological age. GH response to pharmacological stimuli and during sleep was not linked to the pubertal development according to the chronological age. The peak of GH secretion after GHRH injection was significantly delayed in thalassemic patients with retarded puberty. The integrated secretion of GH during the 120-min test was slightly but not significantly reduced in these patients. The prepubertal pattern of GHRH response was restored in the patients receiving substitutive therapy by HCG or testosterone. The alteration of GH response to GHRH in thalassemic patients is likely to be only due to delayed puberty and decreased endogeneous GHRH secretion since it is corrected by androgen or gonadotropin replacement. 相似文献
7.
8.
9.
Rigatelli Gianluca; Braggion Gabriele; Cardaioli Paolo; Faggian Giuseppe 《European heart journal》2007,28(3):309
Embryonic remnants of incomplete septation may complicate occlusiondevice implantation in secundum atrial septal defects (sASD)even if stiff devices such as the Amplatzer Occluder are used. A 35-year-old woman was referred to our center for evaluationof a sASD. 相似文献
10.
Emilio Benfenati Pierluigi Farina Tina Colombo Gianluca De Bellis Mauro Valerio Capodiferro Maurizio D'Incalci 《Cancer chemotherapy and pharmacology》1989,24(6):354-358
Summary The pharmacokinetics of the anticancer agent p-(3,3-dimethyl-1-triazeno) benzoic acid (pCOOH-DMT), a drug now in phase I clinical trial in Europe, was investigated in C57 Bl female mice with M5076 reticulum-cell sarcoma that were treated i.v. with 200 mg/kg pCOOH-DMT. The drug disappeared from plasma with a terminal half-life of about 2.5 h. Plasma clearance was approximately 6 ml/min per kg. Distribution studies showed some differences in drug levels in different tissues. The highest levels were found in the tumor, liver, kidney and lung; lower levels were found in the spleen and gut, and the lowest, in the brain. The N-desmethyl derivative of pCOOH-DMT was not detectable in plasma or tissues of mice treated with the drug. Therefore, the previous evidence of low N-demethylation of pCOOH-DMT was confirmed. pCOOH-DMT glucuronide was identified by mass spectrometry and quantified by high-performance liquid chromatography (HPLC) in plasma, tissues and urine samples. pCOOH-DMT glucuronide appears to be the major urinary metabolite of pCOOH-DMT in mice. Another metabolite identified by mass spectrometry and quantified by HPLC in some tissues and urine was pCOOH-DMT glycinate.Abbreviations DTIlC
5-(3,3-dimethyl-l-triazeno)imidazole-4-carboxamide
- pCOOH-DMT
p-(3,3-dimethyl-l-triazeno)benzoic acid
- pCOOH-MMT
p-(3-methyl-l-triazeno)benzoic acid
- pCONH2-DMT
p-(3,3-dimethyl-l-triazeno)carboxamide
- BSTFA
N,O-bis(trimethylsilyl)trifluoroacetamide
- TMCS
trimethylchlorosilane
- TLC
thin-layer chromatography
- FAB
fast atom bombardment
- EI
electron impact
- M5
M5076 reticulum-cell sarcoma
- t1/2
beta-half-life
- C0
concentration time 0
- AUC
area under the concentration vs time curve
- Cl
total clearance
- V
volume of distribution 相似文献